SLC39A6 and hepatocellular carcinoma: SLC39A6 can influence the epithelial–mesenchymal transition in pancreatic cancer cells, making their phenotype more aggressive [24]; and treatments that target SLC39A6 can reduce metastasis and predict prognosis of patients with hepatocellular carcinoma [25], and it can inhibit progression of metastatic breast cancer [26].